Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
May 25 2023 - 4:30PM
Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of
Stockholders (the “Annual Meeting”) has been adjourned to allow
additional time for stockholders to vote on the proposals set forth
in the Company’s definitive proxy statement filed with the U.S.
Securities and Exchange Commission on April 13, 2023 (the “Proxy
Statement”). The Annual Meeting, originally scheduled to be held on
May 25, 2023 at 8:00 a.m. Eastern Time, and subsequently adjourned,
will reconvene virtually on June 15, 2023 at 8:00 a.m. Eastern
Time, and instructions on participation can be found by visiting
https://www.virtualshareholdermeeting.com/ESPR2023.
No changes have been made to the record date or the proposals to
be brought before the Annual Meeting, which are presented in the
Proxy Statement.
An overwhelming majority of votes cast to date have been cast in
support of each of the director nominees and each of the proposals
in line with the Board of Directors’ recommendations. We do not
yet, however, have a sufficient number of shares cast to approve
all of the proposals. Accordingly, we have opted to reconvene our
Annual Meeting on June 15, 2023 in order to provide stockholders
with additional time to cast their votes. As a reminder,
Esperion’s Board of Directors recommends that stockholders
vote FOR each of the director nominees and FOR Proposals Two,
Three, Four and Five.
Stockholders who have already voted do not need to recast their
votes. Stockholders who have not already voted are
encouraged to do so before June 15, 2023. Proxies
previously submitted in respect of the 2023 Annual Meeting will be
voted at the reconvened meeting unless properly revoked. Only
stockholders of record as of the close of business on March 28,
2023, the record date, are entitled to and are being requested to
vote.
If you are a stockholder of record, there are four ways for you
to vote, including over the Internet by following the instructions
provided in the voting materials you received. Please refer to the
Proxy Statement for additional information about how to vote your
shares.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com
and follow us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information: Investors:
Alexis Callahanmailto:investorrelations@esperion.com(406)
539-1762 Media: Tiffany Aldrich
mailto:corporateteam@esperion.com(616) 443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024